CNS Drugs

, Volume 20, Issue 4, pp 303–310 | Cite as

Long-Term Prophylaxis in Bipolar Disorder

Therapy in Practice


Bipolar disorder is a major cause of disability, and the prevention of relapse is a key management goal. Pharmacological interventions, effectively delivered through enhanced clinical care, are central to long-term management.

This article summarises the available evidence for a range of pharmacological options, and provides guidance on common issues in clinical management in line with current practice guidelines. The use of medications for long-term prophylaxis should be considered in all patients meeting criteria for bipolar I disorder. Increasing high-quality evidence from randomised trials informs management decisions relating to both novel agents, such as lamotrigine and olanzapine, and longer-established therapies, such as lithium and valproate, in monotherapy. Medications taken long-term in bipolar disorder differ in the extent to which they protect against manic and depressive relapse. Consequently, the emerging challenge is to understand how combination treatments can enhance efficacy and effectiveness based on data from controlled trials rather than random polypharmacy.

Clinical care can be enhanced with effective education about the illness, and the use of strategies to improve treatment adherence and the recognition and management of Stressors or prodromal symptoms. Where available, a range of specific psychological interventions can be effective as an adjunct to medication.

When discontinuation of prophylaxis is necessary, gradual tapering of dose over weeks or months is recommended.


  1. 1.
    Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349(9063): 1436–42PubMedCrossRefGoogle Scholar
  2. 2.
    Malhi GS, Mitchell PB, Berk M, et al. Mood stabilizers: a labile label. Acta Psychiatr Scand Suppl 2005; (426): 5-6Google Scholar
  3. 3.
    Goodwin GM, Young AH. The British Association for Psychopharmacology guidelines for treatment of bipolar disorder: a summary. J Psychopharmacol 2003; 17(4 Suppl.): 3–6PubMedGoogle Scholar
  4. 4.
    Grunze H, Kasper S, Goodwin G, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004; 5(3): 120–35PubMedCrossRefGoogle Scholar
  5. 5.
    American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder. 2nd ed. Washington, DC: American Psychiatric Association, 2002Google Scholar
  6. 6.
    Yatham LN, Kennedy SH, Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005; 7Suppl. 3: 5–69PubMedCrossRefGoogle Scholar
  7. 7.
    Kessing LV, Hansen MG, Andersen PK, et al. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders: a life-long perspective. Acta Psychiatr Scand 2004; 109(5): 339–44PubMedCrossRefGoogle Scholar
  8. 8.
    Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005; 7(5): 424–30PubMedCrossRefGoogle Scholar
  9. 9.
    Goodwin GM. Recurrence of mania after lithium withdrawal: implications for the use of lithium in the treatment of bipolar affective disorder. Br J Psychiatry 1994; 164(2): 149–52PubMedCrossRefGoogle Scholar
  10. 10.
    Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161(2): 217–22PubMedCrossRefGoogle Scholar
  11. 11.
    Cipriani A, Wilder H, Hawton K, et al. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomised trials. Am J Psychiatry 2005; 162(10): 1805–19PubMedCrossRefGoogle Scholar
  12. 12.
    Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104(3): 163–72PubMedCrossRefGoogle Scholar
  13. 13.
    Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder: Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000; 57(5): 481–9PubMedCrossRefGoogle Scholar
  14. 14.
    Macritchie KA, Geddes JR, Scott J, et al. Valproic acid, val-proate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001; (3): CD003196Google Scholar
  15. 15.
    Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160(7): 1263–71PubMedCrossRefGoogle Scholar
  16. 16.
    Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65(3): 432–41PubMedCrossRefGoogle Scholar
  17. 17.
    Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162(7): 1281–90PubMedCrossRefGoogle Scholar
  18. 18.
    Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163(2): 247–56PubMedCrossRefGoogle Scholar
  19. 19.
    Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser vs mood stabiliser alone. Br J Psychiatry 2004; 184: 337–45PubMedCrossRefGoogle Scholar
  20. 20.
    Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: a meta-analysis. Acta Psychiatr Scand 1999; 100(6): 406–17PubMedCrossRefGoogle Scholar
  21. 21.
    Greil W, Kleindienst N. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol 1999; 14(5): 277–81PubMedGoogle Scholar
  22. 22.
    Hartong EG, Moleman P, Hoogduin CA, et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64(2): 144–51PubMedCrossRefGoogle Scholar
  23. 23.
    Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry 2001; 62(7): 565–9PubMedCrossRefGoogle Scholar
  24. 24.
    Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry 2003; 160(7): 1252–62PubMedCrossRefGoogle Scholar
  25. 25.
    Soldani F, Ghaemi SN, Tondo L, et al. Relapse after antidepressant discontinuation. Am J Psychiatry 2004; 161(7): 1312–3 [author reply 1313]PubMedCrossRefGoogle Scholar
  26. 26.
    McQuade RD, Sanchez R, Marcus R. Aripiprazole for relapse prevention in bipolar disorder: a 26-week placebo controlled study [abstract] Int J Neuropsychopharmacol 2004; 7(Suppl 1): 161Google Scholar
  27. 27.
    Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58(11): 470–8PubMedCrossRefGoogle Scholar
  28. 28.
    Geddes J, Goodwin G. Bipolar disorder: clinical uncertainty, evidence-based medicine and large-scale randomised trials. Br J Psychiatry 2001; 178Suppl. 41: S191–4PubMedCrossRefGoogle Scholar
  29. 29.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  30. 30.
    Salloum IM, Thase ME. Impact of substance abuse on the course and treatment of bipolar disorder. Bipolar Disord 2000; 2 (3 Pt 2): 269–80PubMedCrossRefGoogle Scholar
  31. 31.
    Scott J, Gutierrez MJ. The current status of psychological treatments in bipolar disorders: a systematic review of relapse prevention. Bipolar Disorders 2004; 6(6): 498–503PubMedCrossRefGoogle Scholar
  32. 32.
    Suppes T, Baldessarini RJ, Faedda GL, et al. Discontinuation of maintenance treatment in bipolar disorder: risks and implications. Harv Rev Psychiatry 1993; 1(3): 131–44PubMedCrossRefGoogle Scholar
  33. 33.
    Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16(3): 165–77PubMedCrossRefGoogle Scholar
  34. 34.
    Brockington IF. Motherhood and mental health. Oxford: Oxford University Press, 1996Google Scholar
  35. 35.
    Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324(10): 674–7PubMedCrossRefGoogle Scholar
  36. 36.
    Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33(2–3): 145–58PubMedCrossRefGoogle Scholar
  37. 37.
    Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975; 87(2): 285–90PubMedCrossRefGoogle Scholar
  38. 38.
    Samren EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999; 46(5): 739–46PubMedCrossRefGoogle Scholar
  39. 39.
    Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium [published erratum appears in JAMA 1994 May 18; vn271 (19): 1485]. JAMA 1994; 271(2): 146–50PubMedCrossRefGoogle Scholar
  40. 40.
    Brockington IF. Puerperal psychosis. In: Brockington IF, editor. Motherhood and mental health. Oxford: Oxford University Press, 1996: 200–84Google Scholar
  41. 41.
    Jones I, Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry 2005; 186: 453–4PubMedCrossRefGoogle Scholar
  42. 42.
    Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161(4): 608–20PubMedCrossRefGoogle Scholar
  43. 43.
    Yoshida K, Smith B, Kumar R. Psychotropic drugs in mothers’ milk: a comprehensive review of assay methods, pharmacokinetics and of safety of breast-feeding. J Psychopharmacol 1999; 13(1): 64–80PubMedCrossRefGoogle Scholar
  44. 44.
    Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: a review. J Clin Psychiatry 2000; 61(2): 79–90PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  1. 1.Department of PsychiatryUniversity of Oxford, Warneford HospitalOxfordUK

Personalised recommendations